The current strategy of CTD Holdings Inc. is to leverage its strong positive cash flow and low debt obligation to invest in its aggressive expansion program of ramping up sales through its bulk manufacturing division NanoSonic Products Inc. NanoSonic Products Inc. will be the main income driver as CTD Holdings Inc. continues to invest in R&D for its pipeline of products currently in various stages of development.
Our revenues are derived from the sales of Cyclodextrin, Cyclodextrin complexes, resale of Cyclodextrins manufactured by others for our clients to their specifications, and our own licensed Cyclodextrin products. We currently sell our products directly to customers in the diagnostics, pharmaceutical, food and industrial chemical industries, as well as to chemical supply distributors. We also offer consulting services to assist our customers in the selection and application of one or more of our products or for general use of Cyclodextrins that does not include the sale of our product.
Our historical business model has been primarily reselling basic Cyclodextrins products, which have the least value-added attributes. Our strategy includes transitioning to the more value-added complexes and increased profitability as good margins can be maintained for these products.
We market and sell Cyclodextrins and related products to the food, pharmaceutical, and other industries. We also provide value-added consulting and knowledge sharing services related to Cyclodextrin technology. Our revenues are principally from the sales of synthetic Cyclodextrins.
The current strategy of CTD Holdings Inc. is to leverage its strong positive cash flow and low debt obligation to invest in its aggressive expansion program of ramping up sales through its bulk manufacturing division NanoSonic Products Inc. NanoSonic Products Inc. will be the main income driver as CTD Holdings Inc. continues to invest in R&D for its pipeline of products currently in various stages of development.Our revenues are derived from the sales of Cyclodextrin, Cyclodextrin complexes, resale of Cyclodextrins manufactured by others for our clients to their specifications, and our own licensed Cyclodextrin products. We currently sell our products directly to customers in the diagnostics, pharmaceutical, food and industrial chemical industries, as well as to chemical supply distributors. We also offer consulting services to assist our customers in the selection and application of one or more of our products or for general use of Cyclodextrins that does not include the sale of our product.Our historical business model has been primarily reselling basic Cyclodextrins products, which have the least value-added attributes. Our strategy includes transitioning to the more value-added complexes and increased profitability as good margins can be maintained for these products.We market and sell Cyclodextrins and related products to the food, pharmaceutical, and other industries. We also provide value-added consulting and knowledge sharing services related to Cyclodextrin technology. Our revenues are principally from the sales of synthetic Cyclodextrins.
การแปล กรุณารอสักครู่..
